Blog

Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

Apr 21 • 3 min read

Bright Minds Biosciences Inc. (CSE:DRUG / NASDAQ:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that the International Searching Authority reviewed its international patent application directed to phenethylamine compounds and issued a Written Opinion indicating that Bright Minds’ core phenethylamine compounds of interest…

Yuriy Blokhin is Empowering Modern Coaches and Therapists – Podcast Episode #27

Apr 19 • 1 min read

On this episode of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Yuriy Blokhin. Yuriy is the Founder and CEO of Homecoming, which is a platform that gives coaches and therapists the tools to do their most impactful work. In this episode, Yuriy talks about his inspiration and why he feels so passionate…

Ways Your Psychedelic Business Can Avoid Insurance Landmines

Apr 18 • 4 min read

Congratulations, you’ve decided to jump in on the psychedelics revolution by starting your own psychedelics company. You’ve got your business plan, your funding is in place, and you’re getting ready to launch. But there’s one critical factor you can’t overlook: proper protection for your company. Maybe you already have some insurance coverage for your business……

Weekly Extractions featuring intelGenx, MindMed, and atai Life Sciences

Apr 18 • 1 min read

In this edition of Weekly Extractions, host Adam Tubero updates us on some big intelGenx news. If you’re unfamiliar with $IGXT, this should be an informative update for you. Beyond that, Adam also shares some updates on MindMed ($MNMD) and atai Life Sciences ($ATAI). Watch the video below for all of the details. Please like,…

FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis

Apr 17 • 4 min read

FSD Pharma Inc. (NASDAQ: HUGE / CSE: HUGE / FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced completion of the first-in-human (“FIH”) sentinel dosing of Lucid-21-302 (“Lucid-MS”) in the Company’s Phase I clinical trial evaluating…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543